STOCK TITAN

MariMed (MRMD) CEO Jon Levine adds 60,000 shares in open-market buys

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MariMed Inc. President and CEO Jon R. Levine reported open-market purchases of 60,000 shares of common stock on May 22, 2026. The buys were executed at prices of $0.0745, $0.0750, and $0.0767 per share. Following these purchases, he directly owns 21,307,986 common shares.

An additional 6,684,640 common shares are held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children. Levine disclaims beneficial ownership of the trust-held shares, meaning they are attributed to the trust rather than to him personally.

Positive

  • None.

Negative

  • None.
Insider Levine Jon R
Role President and CEO
Bought 60,000 shs ($4K)
Type Security Shares Price Value
Purchase Common stock 3,000 $0.0767 $230.10
Purchase Common stock 37,000 $0.075 $3K
Purchase Common stock 20,000 $0.0745 $1K
holding Common stock -- -- --
Holdings After Transaction: Common stock — 21,307,986 shares (Direct); Common stock — 6,684,640 shares (Indirect, By the Jon Levine Family Trust)
Footnotes (1)
  1. F1. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Total shares purchased 60,000 shares Open-market buys on May 22, 2026
Purchase price 1 $0.0745 per share Common stock open-market purchase
Purchase price 2 $0.0750 per share Common stock open-market purchase
Purchase price 3 $0.0767 per share Common stock open-market purchase
Direct holdings after trades 21,307,986 shares Common stock directly owned after purchases
Family trust holdings 6,684,640 shares Held by the Jon Levine Family Trust; beneficial ownership disclaimed
open-market purchase financial
"Purchase in open market or private transaction"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership of these securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"beneficial owner of these securities for purposes of Section 16"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
Family Trust financial
"By the Jon Levine Family Trust"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did MariMed (MRMD) report for Jon R. Levine?

MariMed reported that President and CEO Jon R. Levine bought 60,000 shares of common stock in open-market transactions. These trades on May 22, 2026 occurred at prices between $0.0745 and $0.0767 per share, increasing his direct ownership stake.

At what prices did Jon R. Levine buy MariMed (MRMD) shares?

Jon R. Levine purchased MariMed common stock at $0.0745, $0.0750, and $0.0767 per share. These three open-market purchases on May 22, 2026 totaled 60,000 shares, reflecting small incremental additions at closely grouped price levels.

How many MariMed (MRMD) shares does Jon R. Levine own after these trades?

After the reported purchases, Jon R. Levine directly owns 21,307,986 MariMed common shares. This figure reflects his direct holdings only and excludes additional shares held indirectly through a family trust for which he disclaims beneficial ownership.

What is the Jon Levine Family Trust’s position in MariMed (MRMD) shares?

The Jon Levine Family Trust holds 6,684,640 MariMed common shares. These shares are held for the benefit of Levine’s spouse and children, and he disclaims beneficial ownership of them for Section 16 and other legal purposes, so they are attributed to the trust.

Does Jon R. Levine disclaim beneficial ownership of any MariMed (MRMD) shares?

Yes. Levine disclaims beneficial ownership of shares held by the Jon Levine Family Trust. The trust’s 6,684,640 shares are for his spouse and children, and the disclaimer means the shares are not treated as his personal holdings for Section 16 or similar purposes.

Were there any MariMed (MRMD) insider sales reported for Jon R. Levine?

No insider sales were reported for Jon R. Levine in this Form 4. The filing shows three open-market purchases totaling 60,000 shares and one holding entry, with no dispositions, gifts, tax withholdings, or derivative exercises disclosed in the transaction summary.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Levine Jon R

(Last)(First)(Middle)
C/O MARIMED INC.
10 OCEANA WAY

(Street)
NORWOOD, MASSACHUSETTS 02062

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common stock05/22/2026P3,000A$0.076721,250,986D
Common stock05/22/2026P37,000A$0.07521,287,986D
Common stock05/22/2026P20,000A$0.074521,307,986D
Common stock6,684,640IBy the Jon Levine Family Trust(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Remarks:
/s/ Jon R. Levine05/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)